Generic omeprazole adds a new option for equine gastric disease
Version 1
The treatment landscape for equine gastric disease still centers on accurate diagnosis by gastroscopy, targeted acid suppression, and management changes, but the biggest new development is on the product side: on April 6, 2026, the FDA approved Gastrobim, the first generic omeprazole oral paste for treatment of gastric ulcers and prevention of recurrence in horses and foals 4 weeks of age and older. FDA said Gastrobim is bioequivalent to Gastrogard, the long-established brand approved in 1999, and it remains prescription-only. Beyond that, recent reviews and reference sources continue to stress that equine gastric disease is not one condition: squamous disease generally responds best to omeprazole plus feeding and training adjustments, while glandular disease can be harder to resolve and may require combination approaches such as omeprazole with sucralfate or misoprostol. New retrospective data also reinforce that lesion location may shape how horses present clinically: physical signs were more often linked with squamous disease, while behavioral or mixed signs were more common with glandular or mixed ulceration, adding another reason not to treat all suspected “ulcer” cases as interchangeable. (fda.gov)
Why it matters: For equine veterinarians, the generic approval could improve access and price competition in a category where cost and adherence have long shaped outcomes. But it doesn’t simplify the medicine. Evidence still points to gastroscopy as the standard for diagnosis, omeprazole as the core FDA-approved pharmacologic option, and management as a necessary part of care. Prevention data are strongest in actively training horses, where a meta-analysis found omeprazole prophylaxis reduced ulcer occurrence versus sham treatment, while newer research on nutraceuticals suggests possible biomarker effects without clear endoscopic prevention benefit. The newer clinical-sign study also underscores how nonspecific these cases can be: ulcer severity did not track with sign type, and sport activity was associated with both lesion location and presentation. (fda.gov)
What to watch: Watch whether the generic meaningfully changes prescribing patterns, adherence, and use of compounded alternatives, especially as clinicians continue to refine protocols for glandular disease and recurrence prevention and as more work clarifies how behavioral versus physical signs should influence decisions to scope. (fda.gov)